Stocks · News reference
Barclays Downgrades Dr. Martens to Underweight
Barclays has downgraded its rating for Dr. Martens plc to Underweight and reduced its price target for the company's shares.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Doximity Expands AI Tools and Reports Growth in AI Search Advertising
Doximity is expanding its AI-driven clinical tools and advertising business, reporting significant growth in health system adoption and bookings for its AI Search advertising product.
Doximity, Inc. Reports Second-Quarter Revenue Beat
Doximity, Inc. announced its second-quarter financial results, reporting revenue of $174.54 million, which exceeded analyst expectations.
RBC Capital Markets Raises Price Target on Doximity
RBC Capital Markets increased its price target for Doximity, Inc. (NYSE: DOCS) from $28 to $34 while maintaining an "Outperform" rating.
RBC Capital Maintains Outperform on Doximity, Raises Price Target to $34
Evercore ISI Group Maintains In-Line on Doximity, Lowers Price Target to $33